Ibutilide

Ibutilide
Clinical data
Trade names	Corvert
AHFS/Drugs.com	Monograph
MedlinePlus	a601248
Pregnancy; category	C;
Routes of; administration	Intravenous
ATC code	C01BD05 (WHO) ;
Pharmacokinetic data
Bioavailability	N/A
Protein binding	40%
Metabolism	Hepatic oxidation
Elimination half-life	6 hours (2-12 hours)
Excretion	Renal (82%), fecal
Identifiers
	IUPAC name N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide;
CAS Number	122647-31-8 ;
PubChem CID	60753;
IUPHAR/BPS	7200;
DrugBank	DB00308 ;
ChemSpider	54755 ;
UNII	2436VX1U9B;
KEGG	D08060 ;
ChEMBL	ChEMBL533 ;
CompTox Dashboard (EPA)	DTXSID20861271 ;
Chemical and physical data
Formula	C20H36N2O3S
Molar mass	384.58 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=S(=O)(Nc1ccc(cc1)C(O)CCCN(CC)CCCCCCC)C;
	InChI InChI=1S/C20H36N2O3S/c1-4-6-7-8-9-16-22(5-2)17-10-11-20(23)18-12-14-19(15-13-18)21-26(3,24)25/h12-15,20-21,23H,4-11,16-17H2,1-3H3 ; Key:ALOBUEHUHMBRLE-UHFFFAOYSA-N ;
	(verify)

Ibutilide is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm. It exerts its antiarrhythmic effect by induction of slow inward sodium current, which prolongs action potential and refractory period of myocardial cells. Because of its Class III antiarrhythmic activity, there should not be concomitant administration of Class Ia and Class III agents.

Ibutilide is marketed as Corvert by Pfizer. Administration resulted in successful heart rhythm control in 31–44% of patients within 90 minutes, with sustained polymorphic ventricular tachycardia in 0.9–2.5% of patients. It appears to show better results in atrial flutter as compared to atrial fibrillation.^[1]

^ Kowey PR, Stoenescu ML (2005). "Selection of drugs in pursuit of a rhythm control strategy". Progress in Cardiovascular Diseases. 48 (2): 139–45. doi:10.1016/j.pcad.2005.06.009. PMID 16253653.

[RythmControl-1] Kowey PR, Stoenescu ML (2005). "Selection of drugs in pursuit of a rhythm control strategy". Progress in Cardiovascular Diseases. 48 (2): 139–45. doi:10.1016/j.pcad.2005.06.009. PMID 16253653.

[1]